SCHEMBL5270396

SCHEMBL5270396

OB(O)c1cccc(-c2cnco2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
MAP4K4 O95819 1/20 0.58
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
MGLL Q99685 1/20 0.50
PTK2 Q05397 1/20 0.46
HDAC4 P56524 1/20 0.44
NOTUM Q6P988 1/20 0.43
GAA P10253 1/20 0.43
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
PDK2 Q15119 1/20 0.41
ENPP2 Q13822 2/20 0.40
IL2 P60568 1/20 0.40
KEAP1 Q14145 1/20 0.40
IMPDH2 P12268 1/20 0.40
BRAF P15056 1/20 0.39
PLG P00747 1/20 0.39
F12 P00748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158739 0.82 KMT2A (0.75) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL12260635 0.79 PKM (0.58) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL9955698 0.77 MEN1 (0.64) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL3510121 0.77 MEN1 (0.64) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL29808221 0.75 KMT2A (0.66) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL949044 0.74 KMT2A (0.55) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL3147405 0.74 MEN1 (0.64) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL4755701 0.74 MEN1 (1.00) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL7980113 0.74 MEN1 (0.64) MEN1KMT2AMAP4K4CYP11B1CYP11B2
SCHEMBL29722919 0.74 MAP4K4 (1.00) MEN1KMT2AMAP4K4CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802721-B2 Thiophene compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-08-12 US disclosed
EP-1846388-A1 THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2007-10-24 EP disclosed
US-20060199845-A1 Thiophene compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2006-09-07 US disclosed
WO-2006081389-A1 THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199845-A1 Thiophene compounds for inflammation and immune-related uses CXCR2, TPMT, CXCR1 MEN1 4484/4885KMT2A 3925/4885MAP4K4 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.